ERK pathway inhibitors: How low should we go? Journal Article
| Authors: | Nissan, M. H.; Rosen, N.; Solit, D. B. |
| Article Title: | ERK pathway inhibitors: How low should we go? |
| Abstract: | Resistance to RAF inhibitors is generally accompanied by reactivation of extracellular signal-regulated kinase (ERK) signaling. SCH772984, a selective, ATP-competitive inhibitor of ERK1 and ERK2, is effective in BRAF-mutant models in which resistance is the result of ERK reactivation. SCH772984 may also have a role in the treatment of tumors in which ERK is dysregulated by mutant RAS, NF1, or activated receptor tyrosine kinases, settings in which current RAF inhibitors are ineffective. © 2013 American Association for Cancer Research. |
| Journal Title: | Cancer Discovery |
| Volume: | 3 |
| Issue: | 7 |
| ISSN: | 2159-8274 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2013-07-01 |
| Start Page: | 719 |
| End Page: | 721 |
| Language: | English |
| DOI: | 10.1158/2159-8290.cd-13-0245 |
| PROVIDER: | scopus |
| PUBMED: | 23847348 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 August 2013" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work